Pfizer announced Phase 3 results showing its PARP inhibitor Talzenna (talazoparib) combined with standard therapy met primary endpoints in prostate cancer, and the company said it will seek regulatory label expansion to earlier lines of care. The data came as Pfizer continues commercial integration after acquiring Talzenna in a prior deal. Analysts flagged that earlier‑line use could materially expand the drug’s addressable market after initially slow uptake in later lines. Pfizer framed the results around response and survival signals that may shift prescribing patterns and justify moving Talzenna into frontline settings.